Nintedanib, pirfenidona y células madre como tratamiento de las enfermedades pulmonares intersticiales fibrosantes progresivas

Abstract

Progressive fibrosing interstitial lung diseases are made up of a group of pathologies that occur when fibrosis progresses despite therapeutic measures. The treatment of these pathologies continues under investigation, since in recent years antifibrotic drugs have been developed that promise to improve the patient's quality of life and slow down the progression of the disease, to this are added the new stem cell transplant studies that do not They only show an acceptable and well-tolerated safety profile, but rather manageable adverse effects. A narrative bibliographic review was carried out, the objective of which is to describe Nintedanib, Pirfenidone and stem cells as a treatment for progressive fibrosing interstitial lung diseases. The findings of this investigation were that Nintedanib and Pirfenidone slow down the decrease in Forced Vital Capacity, the risk of mortality is higher in patients with idiopathic fibrosis than in other types of fibrosis, the most common adverse effects associated with Nintedanib are diarrhea, nausea , vomiting and headache, while with Pirfenidone it is gastrointestinal disorders, fatigue, skin rashes, dizziness, photosensitivity and weight loss. Stem cell therapy demonstrates safety and tolerable and manageable adverse effects.